The new owner of Bausch & Lomb Inc. is looking to make $800 million in cuts.
The Rochester Business Journal reports that Valeant Pharmaceuticals International Inc. hopes to greatly reduce the Rochester company's sales, general and administrative expenses.
Those costs -- abbreviated as SG&A -- now account for about 40 percent of Bausch & Lomb's expenses. But Valeant officials say they want SG&A to be in the range of 20 percent.
Valeant's $8.7 billion acquisition of Bausch & Lomb was announced on Monday.